Adlai Nortye (ANL) Registration Filing summary

Company overview and business model

• Operates as a global clinical-stage biopharmaceutical company focused on innovative cancer therapies, with dual R&D presence in the U.S. and China.

• Pipeline targets next-generation cancer immunotherapies and RAS-driven cancers, including proprietary candidates such as AN8025, AN4005, AN9025, and AN4035.

• Incorporated in the Cayman Islands, with principal operations through subsidiaries in the U.S. and mainland China.

• Became publicly traded on Nasdaq in September 2023 under the symbol “ANL.”

Financial performance and metrics

• The company’s consolidated financial statements as of December 31, 2024, include a going concern explanatory paragraph and a revision to previously issued financials.

• Financial statements audited by BDO China Shu Lun Pan Certified Public Accountants LLP and Mazars USA LLP.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for general corporate purposes, including capital expenditures, working capital, and other business opportunities.

• No proceeds will be received from the sale of securities by selling shareholders; company will bear registration costs, while selling shareholders bear their own selling expenses.